Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jiedu Huayu Oral Prescription in CAA-Associated Intracranial Hemorrhage
NCT07250035Phase 3Recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jan 2026
- Primary completion
- Nov 2028
- Modality
- HM (Herbal Medicine), TCM (Traditional Chinese Medicine)
- Countries
- 1
01
Overview
A Phase 3 trial of Jiedu Huayu in cerebral amyloid angiopathy (CAA), intracranial hemorrhage (ICH), sponsored by Beijing Tiantan Hospital. Started Jan 2026; status: recruiting.
02
Drugs
Jiedu Huayu
03
Conditions
cerebral amyloid angiopathy (CAA)intracranial hemorrhage (ICH)
Beyond the preview
Go deeper on NCT07250035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07250035.